Insurers need more evidence of long-term safety and efficacy to make the best decisions about whether — and how — to cover Eisai’s Leqembi (lecanemab) for early Alzheimer’s disease, according to experts who participated in a policy discussion with the Institute for Clinical and Evidence Review (ICER).
Source: Drug Industry Daily